The Catalyst

Most Recent Posts

04.19.13 | By Preet Bilinski

Every year, the PhRMA Foundation grants Awards in Excellence to past awardees who are dramatic, living proof that the Foundation program works and makes a difference. These awards are given to scientists who received a Foundation grant at the outset of their careers and went on to distinguish themselves through their scientific and/or academic achievements.

04.19.13 | By Kaelan Hollon

The Research In Your Backyard (RIYB) event was a bright spot of hope amid an otherwise overcast day in Augusta, and PhRMA President and CEO (and longtime Maine resident) John Castellani spoke to his hometown crowd about the impact of clinical trials in Maine. With more than 560 clinical trials that have been conducted or are still occurring in the state in the past 13 years, the RIYB program provides an important message of hope to both patients and the state's economy.

04.16.13 | By Kaelan Hollon

Today there was legislation introduced by several members of Congress that would impose mandatory government price controls in the form of rebates in Medicare Part D.

04.12.13

A strong finish to #PhRMA13 today drove home the message that for patients, there is no greater source of hope than the continued medical innovation that leads to new treatments and further, new hope. 

04.12.13 | By Robert J. Hugin

The past few days have been an excellent reminder of the accomplishments of our organization during the past year under the leadership of Dr. John Lechleiter. We have made important progress in our ongoing mission to protect and expand medical innovation and provide patients with access to disease-altering new therapies.

04.12.13

It’s obvious at #PhRMA13 that providing patients with the treatments they need is at the forefront of everyone’s mind. To determine what treatments are needed, patient engagement is becoming increasingly important.

04.11.13 | By Kaelan Hollon

The third and final panel today at #PhRMA13 tried on a new definition of what we consider "disruptive", and why we should like it.  A disruptive technology or innovation improves not just what is known, but changes the modus operandi in completely unforeseen ways.

04.11.13

I’m at the PhRMA 2013 Annual Meeting in San Diego, where a panel is discussing disruptive innovation and the new challenges and opportunities it opens for the biopharmaceutical industry.

It’s a great topic. 

04.11.13 | By Kaelan Hollon

The morning panels of PhRMA's Annual Meeting provided a welcome blast of new thinking on how to create a positive geography for innovation, and further how that science gets done. As an added bonus, California Lieutenant Governor Gavin Newsom gave a super-charged address explaining how a state in grave economic flux plans to keep their leadership in bioscience.

04.11.13

Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.

04.11.13

John Castellani, PhRMA’s president & CEO, opened today’s afternoon session of PhRMA’s Annual Meeting in San Diego in a speech calling on policymakers, healthcare stakeholders, biopharmaceutical industry critics and sector allies alike to recognize and leverage the value of innovative medicines.

04.11.13

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980. 

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.  

04.11.13 | By Kaelan Hollon

There is certainly no lack of talent in the biopharmaceutical industry. Every day, employees are working hard in a variety of roles to ensure that patients get the treatments they need. It isn’t just the research scientists in the lab, it’s sales executives and communications staff who go above and beyond to advance research, progress and hope in everything they do.

04.11.13 | By John Crosby

The second #PhRMA13 panel begins at 1:45 pm EDT and will address medical breakthroughs and what needs to change to speed personalized medicine to patients. In a guest post, John Crosby, Executive Director at the American Osteopathic Association, addresses what he believes is necessary to bring science from the lab to the patient.

04.11.13 | By John Lechleiter, Ph.D.

PhRMA Chairman and Lilly President and CEO John Lechleiter is kicking off #PhRMA13 now. In a guest post he discusses the future of the industry. To learn more watch live now!

04.11.13 | By Jon Tripp

As we gear up for discussion today around research, progress and hope at our 2013 Annual Meeting in San Diego, we are enthusiastic about the re-launch of our website, PhRMA.org.

04.10.13

Today is a big day at Lilly. Not only does our CEO, John Lechleiter, begin chairing the PhRMA annual meeting, but we’re also launching a new digital communications platform that will enhance our conversations with media who cover the biopharmaceutical industry.

04.09.13

In Washington last week it was still winter.  Suddenly, with temperatures in the 80’s it is summer with a vengeance.  The caprice of weather (it is snowing in Denver today and was in the 70s over the weekend) should remind us all how we all may be vulnerable in a weather emergency – especially a hurricane, flood or

04.09.13

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980.

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.

04.09.13 | By Stephanie Fischer

Pages